Antibiotic resistance

Journal of Medical Microbiology

Volumn 46, Issue 6, 1997, Pages 436-470

  Amyes, S G B ^a   Gemmell, C G ^b   Gransden, W R ^c  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CARBAPENEM DERIVATIVE; CARBOMYCIN; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CHLORTETRACYCLINE; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); ERYTHROMYCIN; GENTAMICIN; IMIPENEM; KANAMYCIN; LINCOMYCIN; MEROPENEM; NEOMYCIN; NOVOBIOCIN; PAROMOMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEICOPLANIN; TETRACYCLINE; TRIMETHOPRIM; TYLOSIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL METABOLISM; CONFERENCE PAPER; ENTEROBACTER; ESCHERICHIA COLI; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS; STAPHYLOCOCCUS; STREPTOCOCCUS; ARTICLE; BACTEREMIA; CROSS INFECTION; DRUG EFFECT; GRAM NEGATIVE BACTERIUM; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MULTIDRUG RESISTANCE;

ANTI-BACTERIAL AGENTS; BACTEREMIA; CROSS INFECTION; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 0030991231     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/00222615-46-6-436     Document Type: Conference Paper

References (264)

1. Kolmer JA. Septicaemia. Ann Int Med 1934; 8: 612-631.
2. McGowan JE, Barnes MW, Finland M. Bacteremia at Boston City Hospital: occurrence and mortality during 12 selected years (1935-1972), with special reference to hospital-acquired cases. J Infect Dis 1975; 132: 316-335.
3. McGowan JE. Changing etiology of nosocomial bacteremia and fungemia and other hospital-acquired infections. Rev Infect Div 1985; 7 Suppl 3: S357-S370.
4. Mylotte JM, White D, McDermott C, Hodan C. Nosocomial bloodstream infection at a veterans hospital; 1979 to 1987. Infect Control Hosp Epidemiol 1989; 10: 455-464.
5. Murray BE. New aspects of antimicrobial resistance and the resulting therapeutic dilemmas. J Infect Dis 1991; 163: 1184-1194.
6. Bergogne-Berezin E, Joly-Guillou ML. Hospital infection with Acinetobacter spp.: an increasing problem. J Hosp Infect 1991; 18 Suppl B: 250-255.
7. Sirot D. Extended-spectrum plasmid-mediated β-lactamases. J Antimicrob Chemother 1995; 36 Suppl A: 19-34.
8. Hibbert-Rogers LCF, Heritage J, Gascoyne-Binzi DM et al. Molecular epidemiology of ceftazidime resistant Enterobacteriaceae from patients on a paediatric oncology ward. J Antimicrob Chemother 1995; 36: 65-82.
9. Shannon KP, Phillips I. A computer program for the storage and analysis of minimum inhibitory concentrations of antimicrobial agents. Binary 1990; 2: 89-95.
10. Gransden WR, Eykyn SJ, Phillips I. The computerized documentation of septicaemia. J Antimicrob Chemother 1990; 25 Suppl C: 31-39.
11. Spencer RC. Nosocomial infection in the intensive care unit: a question of surveillance. Intensive Care World 1993; 10: 173-176.
12. Koontz FP. Microbial resistance surveillance techniques. Blood cultures versus multiple body site monitoring. Diagn Microbiol Infect Dis 1992; 15 Suppl 2: 31S-35S.
13. Walder M, Karlsson E, Nilsson B. Sensitivity of 880 blood culture isolates to 24 antibiotics. Scand J Infect Dis 1994; 26: 67-75.
14. Moller JK. Antimicrobial usage and microbial resistance in a university hospital during a seven-year period. J Antimicrob Chemother 1989; 24: 983-992.
15. Emmerson AM, Enstone JE, Griffin M, Kelsey MC, Smyth ETM. The Second National Prevalence Survey of infection in hospitals overview of the results. J Hosp Infect 1996; 32: 175-190.
16. Geerdes HF, Ziegler D, Lode H et al. Septicemia in 980 patients at a university hospital in Berlin: prospective studies during 4 selected years between 1979 and 1989. Clin Infect Dis 1992; 15: 991-1002.
17. Eykyn SJ, Gransden WR, Phillips I. The causative organisms of septicaemia and their epidemiology. J Antimicrob Chemother 1990; 25 Suppl C:41-58.
18. Johnson AP, Speller DCE, George RC, Warner M, Domingue G, Efstratiou A. Prevalence of antibiotic resistance and serotypes in pneumococci in England and Wales: results of observational surveys in 1990 and 1995. BMJ 1996; 312: 1454-1456.
19. Fomsgaard A, Hoiby N, Friis HM et al. Prevalence and antibiotic sensitivity to Danish versus other European bacterial isolates from intensive care and hematology/ oncology units. Eur J Clin Microbiol Infect Dis 1995; 14: 275-281.
20. Fass RJ, Barnishan J, Avers LW. Emergence of bacterial resistance to imipenem and ciprofloxacin in a university hospital. J Antimicrob Chemother 1995; 36: 343-353.
21. Cometta A, Calandra T, Bille J, Glauser MP. Escherichia coli resistant to fluoroquinolones in patients with cancer neutropenia. N Engl J Med 1994; 300: 1240-1241.
22. Carratalá J, Fernández-Sevilla A, Tubau F, Callis M, Gudiol F. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis 1995; 20: 557-560.
23. Kunova A, Trupl J, Krcmery V Low incidence of quinolone resistance in gram-negative bacteria after five-years use of ofloxacin in prophylaxis during afebrile neutropenia. J Hosp Infect 1996; 32: 155-156.
24. Liu PYF, Gur D, Hall LMC, Livermore DM. Survey of the prevalence of β-lactamases amongst 1000 Gram-negative bacilli isolated consecutively at the Royal London Hospital. J Antimicrob Chemother 1992; 30: 429-447.
25. Mayer KH. The epidemiology of antibiotic resistance in hospitals. J Antimicrob Chemother 1986; 18 Suppl C: 223-233.
26. Bergogne-Bérézin E, Decré D, Joly-Guillou M-L. Opportunistic nosocomial multiply resistant bacterial infections - their treatment and prevention. J Antimicrob Chemother 1993; 32 Suppl A: 39-47.
27. Neu HC. The crisis of antibiotic resistance. Science 1992; 257: 1064-1073.
28. Tenover FC, McGowan JE. Reasons for the emergence of antibiotic resistance. Am J Med Sci 1996; 311: 9-16.
29. Scaife W, Young H-K, Paton RH, Amyes SGB. Transferable imipenem-resistance in Acinetobacter species from a clinical source. J Antimicrob Chemother 1995; 36: 585-586.
30. O'Brien TF and the International Survey of Antibiotic Resistance Group. Resistance to antibiotics at medical centres in different parts of the world. J Antimicrob Chemother 1986; 18 Suppl C: 243-253.
31. Cookson BD. Progress with establishing and implementing standards for infection control in the UK. J Hosp Infect 1995; 30 Suppl: 69-75.
32. WHO Scientific Working Group on monitoring and management of bacterial resistance to antimicrobial agents. World Health Organization, Geneva. 1994.
33. Department of Health and PHLS Working Group. The prevention and management of Clostridium difficile infection. Heywood, BAPS Health Publications Unit. 1994.
34. Report of the Public Health Laboratory Service. Incidence of surgical wound infection in England and Wales. Lancet 1960: 2: 659-663.
35. Sartor C, Edwards JR, Gaynes RP, Culver DH. National Nosocomial Infections Surveillance System. Evolution of hospital participation in the National Nosocomial Infections Surveillance System 1986 to 1993. Am J Infect Control 1995; 23: 364-368.
36. Wegelt JA, Dryer D, Haley RW. The necessity and efficiency of wound surveillance after discharge. Arch Surg 1992; 127: 77-82.
37. Rahman A, Mackenzie D, Marples R, Cookson BD. Identification of MRSA incidents in hospitals. J Hosp Infect 1995; 30: 76-78.
38. National Nosocomial Infections Surveillance (NNIS) System. Nosocomial infection rates for interhospital comparison: limitations and possible solution. Infect Control Hosp Epidemiol 1991; 12: 609-621.
39. Schaberg DR, Culver DH, Gaynes RP. Major trends in the microbial etiology of nosocomial infection. Am J Med 1991; 91: 72S-75S.
40. Panlilio AL, Culver DH, Gaynes RP et al. Methicillin-resistant Staphylococcus aureus in US hospitals, 1975-1991. Infect Control Hosp Epidemiol 1992; 13: 582-586.
41. Meers PD, Ayliffe GAJ, Emmerson AM et al. Report on the National Survey of Infection in Hospitals 1980. J Hosp Infect 1981; 2: Suppl: 1-51.
42. Olson MM, Lee JT. Continuous 10-year wound infection surveillance. Results, advantages, and unanswered questions. Arch Surg 1990; 125: 794-803.
43. Marples RR, Reith S. Methicillin-resistant Staphylococcus aureus in England and Wales. CDR Review 1992; 2: R25-29.
44. Report of a Combined Working Party of the Hospital Infection Society and the British Society of Antimicrobial Chemotherapy. Revised guidelines for the control of epidemic methicillin-resistant Staphylococcus aureus. J Hosp Infect 1990; 16: 351-377.
45. Cox RA, Mallaghan C, Conquest C, King J. Epidemic methicillin-resistant Staphylococcus aureus: controlling the spread outside hospital. J Hosp Infect 1995; 29: 107-119.
46. Cox RA, Conquest C, Mallaghan C, Marples RR. A major outbreak of methicillin-resistant Staphylococcus aureus caused by a new phage-type (EMRSA-16). J Hosp Infect 1995; 29: 87-106.
47. Cookson BD, Peters B, Webster M, Phillips I, Rahman N, Noble W. Staff carriage of epidemic methicillin-resistant Staphylococcus aureus. J Clin Microbiol 1989; 27: 1471-1476.
48. Marples RR, Speller DCE, Cookson BD. Prevalence of mupirocin resistance in Staphylococcus aureus. J Hosp Infect 1995; 29: 153-155.
49. Spera RV, Farber BF. Multiply-resistant Enterococcus faecium. The nosocomial pathogen of the 1990s. JAMA 1992; 268: 2563-2564.
50. Anon. Nosocomial enterococci resistant to vancomycin United States 1989-1993. MMWR Morbid Mortal Wkly Rep 1993; 42: 597-599.
51. Uttley AH, George RC, Naidoo J et al. High-level vancomycin-resistant enterococci causing hospital infections. Epidemiol Infect 1989; 103: 173-181.
52. Wade JJ. The emergence of Enterococcus faecium resistant to glycopeptides and other standard agents a preliminary report. J Hosp Infect 1995; 30 Suppl: 483-493.
53. Wade JJ, Desai N, Casewell MW. Hygienic hand disinfection for the removal of epidemic vancomycin-resistant Enterococcus faecium and gentamicin-resistant Enterobacter cloacae. J Hosp Infect 1991; 18: 211-218.
54. Anon. Vancomycin resistant enterococci in hospitals in the United Kingdom. Commun Dis Rep CDR Weekly 1995; 5: 281-284.
55. Murray BE. The life and times of the Enterococcus. Clin Microbiol Rev 1990; 3: 46-65.
56. Gautom RK, Stewart B, Coyle MB, Plorde JJ, Schoenknecht FD, Pritsche TR. Pulsed field gel electrophoretic analysis of vancomycin resistant enterococci (VREs) recovered from Seattle hospitals (Abstract). Am J Clin Pathol 1995; 104: 223.
57. Hospital Infection Control Practices Advisory Committee (HICPAC). Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol 1995; 16: 105-113.
58. Rice LB. The theoretical origin of vancomycin-resistant enterococci. Clin Microbiol Newslett 1996; 17: 24; 189-192.
59. Klare I, Heier H, Claus H, Reissbrodt R, Witte W. vanA-mediated level glycopeptide resistance in Enterococcus faecium from animal husbandry. FEMS Microbiol Lett 1995; 125: 165-171.
60. Brown S, Amyes SGB, Thomson CJ. Antibiotic resistance in Haemophilus influenzae isolated in England and Wales. 1st European Congress of Chemotherapy. Carnforth. Lanes. Parthenon Publishing. 1996. Abstract T135.
61. Scriver SR, Walmsley SL, Kau CL et al. Determination of antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae and characterization of their β-lactamases. Antimicrob Agents Chemother 1994; 38: 1678-1680.
62. Shanahan PMA, Thomson CJ, Amyes SGB. Antibiotic susceptibilities of Haemophilus influenzae in central Scotland. Clin Microbiol Infect 1: 168-174.
63. Reid AJ, Simpson IN, Harper PB, Amyes SGB. Ampicillin resistance in Haemophilus influenzae: identification of resistance mechanisms. J Antimicrob Chemother 1987; 20: 645-656.
64. Vali L, Lindsay G, Thomson CJ, Amyes SGB. β-lactamases in Haemophilus influenzae isolated in Glasgow. 94th Annual Meeting of the ASM. Washington, DC, American Society for Microbiology. 1994. Abstract A-72.
65. Damn RS, Murphey-Corb M, Shapira S, Dipp S. Epidemiology of ROB β-lactamase among ampicillin-resistant Haemophilus influenzae isolates in the United States. J Infect Dis 1988; 157: 450-455.
66. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995; 39: 1211-1233.
67. Vali L, Thomson CJ, Amyes SGB. Incidence of β-lactam resistance in Haemophilus influenzae. 95th Annual Meeting of the ASM. Washington, DC, American Society for Microbiology. 1995. Abstract A-81.
68. Vali L, Thomson CJ, Amyes SGB. Haemophilus influenzae: identification of a novel β-lactamase. J Pharm Pharmacol 1994; 46: Suppl 2: 1041.
69. Retsema J, Girard A, Schelkly W et al. Spectrum and mode of action of azithromycin (CP-62, 993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. Antimicrob Agents Chemorher 1987; 31: 1939-1947.
70. Roberts M, Corney A, Shaw WV. Molecular characterization of three chloramphenicol acetyltransferases isolated from Haemophilus influenzea. J Bacteriol 1982; 151: 737-741.
71. Burns JL, Mendelman PM, Levy J, Stull TL. Smith AL. A permeability barrier as a mechanism of chloramphenicol resistance in Haemophilus influenzea. Antimicrob Agents Chemother 1985; 27: 46-54.
72. Speer, BS, Shoemaker NB, Salvers AA. Bacterial resistance to tetracycline: mechanisms, transfer, and clinical significance. Clin Microbiol Rev 1992; 5: 387-399.
73. Jahn G, Laufs R, Kaulfers P-M, Kolenda H. Molecular nature of two Haemophilus influenzea R factors containing resistances and the multiple integration of drug resistance transposons. J Bacteriol 1979; 138: 584-597.
74. de Groot R, Chaffin DO, Kuehn M, Smith AL. Trimethoprim resistance in Haemophilus influenzea is due to altered dihydrofolate reductases(s). Biochem J 1991; 274: 657-662.
75. Gould IM, Forbes KJ, Gordon GS. Quinolone resistant Haemophilus influenzea. J Antimicrob Chemother 1994; 33: 187-188.
76. Steingrube VA, Wallace RJ, Beaulieu D. A membrane-bound precursor β-lactamase in strains of Moraxella catarrhalis and Moraxella nonliquefaciens that produce periplasmic BRO-1 and BRO-2 β-lactamases. J Antimicrob Chemother 1993; 31: 237-244.
77. Simpson IN, Plested SJ. The origin and properties of β-lactamase satellite bands seen in isoelectric focusing. J Antimicrob Chemother 1983; 12: 127-131.
78. Christensen JJ, Keiding J, Schumacher H, Bruun B. Recognition of a new Branhamella catarrhalis β-lactamase-BRO-3. J Antimicrob Chemother 1991; 28: 774-775.
79. Wallace RJ, Steingrube VA, Nash DR et al. BRO β-lactamase of Branhamella catarrhalis and Moraxella subgenus Moraxella, including evidence for chromosomal β-lactamase transfer by conjugation in B, catarrhalis, M. nonliquefaciens and M. lacunata. Antimicrob Agents Chemother 1989; 33: 1845-1854.
80. Liñares J, Pallares R, Alonso T et al. Trends in antimicrobiol resistance of clinical isolates of Streptococcus pneumoniae in Bellvitge hospital, Barcelona, Spain (1979 1990). Clin Infect Dis 1992; 15: 99-105.
81. Marion A. Pneumococcal antimicrobial resistance: the problem in Hungary. Clin Infect Dis 1992; 15: 106-111.
82. Koornhof HJ, Wasas A, Klugman K. Antimicrobial resistance in Streptococcus pneumoniae: a South African perspective. Clin Infect Dis 1992; 15: 84-94.
83. Reichmann P, Varon H, Günther E et al. Penicillin-resistant Streptococcus pneumoniae in Germany: genetic relationship to clones from other European countries. J Med Microbiol 1995; 43: 377-385.
84. Appelbaum PC. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin Infect Dis 1992; 15: 77-83.
85. Spratt BG. Resistance to antibiotics mediated by target alterations. Science 1994; 264: 388-393.
86. Schutze GE, Kaplan SL, Jacobs RK. Resistant pneumococcus: a worldwide problem. Infection 1994; 22: 233-237.
87. Shaw WV. Chloramphenicol acetyltransferase: enzymology and molecular biology. CRC Crit Rev Biochem 1983; 14: 1-46.
88. Burdett V. Purification and characterization of Tet(M), a problem that renders ribosomes resistant to tetracycline. J Biol Chem 1941; 266: 2872-2877.
89. Weisblum B. Inducible resistance to macrolides, lincosamides and streptogramin type B antibiotics: the resistance pheno-type. its biological diversity, and structural elements that regulate expression - a review. J Antimicrob Chemother 1985; 16 Suppl A: 63-90.
90. George RC, Ball LC, Cooper PG. Antibiotic resistant pneumococci in the United Kingdom. CDR Rev 1992; 2: R37-R43.
91. George RC, Norbury PB, James D. Surveillance of antibiotic resistance in England and Wales. J Med Microbiol 1992; 36: 17-20.
92. Aszkenasy OM, George RC, Begg NT. Pneumococcal bacteraemia and meningitis in England and Wales 1982 to 1992. Commun Dis Rep CDR Rev 1995; 5: R45-R50.
93. Anon. Antimicrobial resistance of pneumococci isolated from blood and cerebrospinal fluid, 1993 and 1994. Commun Dis Rep CDR Weekly 1995; 5: 187-188.
94. Wenzel RP, Nettleman MD, Jones RN, Pfaller MA. Methicillin-resistant Staphylococcus aureus: implications for the 1990s and effective control measures. Am J Med 1991; 91 Suppl B: 221S-227S.
95. Marples RR, Reith S. Methicillin-resistant Staphylococcus aureus in England and Wales. Commun Dis Rep CDR Rev 1992; 2: R25-29.
96. Anon. Epidemic methicillin-resistant Staphylococcus aureus. Commun Dis Rep CDR Rev 1996; 6: 197.
97. Friedland IR. Treatment of pneumococcal infections in the era of increasing penicillin resistance. Curr Opin Infect Dis 1995; 8: 213-217.
98. French GL, Cheng AFB, Ling JML, Mo P, Donnan S. Hong Kong strains of methicillin-resistant and methicillin-sensitive Staphylococcus aureus have similar virulence. J Hosp Infect 1990; 15: 117-125.
99. Vincent JL, Bihari PJ, Suter PM et al. The prevalence of nosocomial infection in intensive care units in Europe results of the European prevalence of infection in intensive-care (HPIC) study. EPIC International Advisory Committee JAMA 1995; 274: 639-644.
100. Emori TG, Gaynes RP. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev 1993; 6: 428-442.
101. Maki DG, Agger WA. Enterococcal bacteremia: clinical features, the risk of endocarditis and management. Medicine 1988; 67: 248-269.
102. Handwerger S, Raucher B, Altarac D et al. Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin. penicillin and gentamicin. Clin Infect Dis 1993; 16: 750-755.
103. Cotterill S, Evans R, Fraise AP. An unusual source for an outbreak of methicillin-resistant Staphylococcus aureus on an intensive therapy unit. J Hosp Infect 1996; 32: 207-216.
104. Jacobson KL, Cohen SH, Inciardi JF et al. The relationship between antecedent antibiotic use and resistance to extended-spectrum cephalosporins in Group 1 β-lactamase-producing organisms. Clin Infect Dis 1995; 21: 1107-1113.
105. Ballow CH, Schentag JJ. Trends in antibiotic utilization and bacterial resistance. Report of the National Nosocomial Resistance Surveillance Group. Diagn Microbiol Infect Dis 1992; 15 Suppl 2: 37S-42S.
106. Bamberger DM, Dahl SL. Impact of voluntary vs enforced compliance of third-generation cephalosporin use in a teaching hospital. Arch Intern Med 1992; 152: 554-557.
107. Leelercq R, Derlot E, Duval J, Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 1988; 319: 157-161.
108. Centers for Disease Control and Prevention. Nosocomial enterococci resistant to vancomycin - United States 1989-1993. Morb Mort Weekly Rep 1993; 42: 597-599.
109. Woodford N, Morrison D, Johnson AP et al. Plasmid mediated VanB glycopeptide resistance in enterococci. Microb Drug Res 1995; 1: 235-240.
110. Edmond MB, Ober JF, Weinbaum DL et al. Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis 1995; 20: 1126-1133.
111. Hastings JGM, Jolley AJ. Vancomycin resistant and dependent enterococci in a tertiary referral centre. 35th ICAAC. San Francisco, Washington, DC, American Society for Microbiology. 1995. Abstract.
112. Woodford N, Morrison D, Johnson AP, Briant V, George RC, Cookson B. Application of DNA probes for rRNA and VanA genes to investigation of a nosocomial cluster of vancomycin-resistant enterococci. J Clin Microbiol 1993; 31: 653-658.
113. Sader HS, Pfaller MA, Tenover FC, Hollis RJ, Jones RN. Evaluation and characterization of multiresistant Enterococcus faecium from 12 US Medical Centers. J Clin Microbiol 1994; 32; 2840-2842.
114. Bates J, Jordens JZ, Griffiths DT. Farm animals as a putative reservoir for vancomycin-resistant enterococci infection in man. J Antimicrob Chemother 1994; 34: 507-516.
115. Centers for Disease Control and Prevention. United States: Federal Register. Preventing the spread of vancomycin resistance. 1994; 59: 257-263.
116. Arthur M, Molinas C, Depardieu F, Courvalin P. Characterization of Tn 1546, a Tn3-related transposon conferring glycopeptide resistance by synthesis of depsipeptide peptidoglycan precursors in Enterococcus faecium BM4147. J Bacteriol 1993; 175: 117-127.
117. Arthur M, Courvalin P. Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother 1993; 37: 1563-1571.
118. Messer J, Reynolds PE. Modified peptidoglycan precursors produced by glycopeptide-resistant enterococci. FEMS Microbiol Lett 1992; 73: 95-200.
119. Quintiliani R, Evers S, Courvalin P. The vanB gene confers various levels of self-transferable resistance to vancomycin in enterococci. J Infect Dis 1993; 167: 1220-1223.
120. Evers S, Reynolds PE, Courvalin P. Sequence of the vanB and ddl genes encoding D-alanine: D-lactate and D-alanine ligases in vancomycin-resistant Enterococcus faecalis V583. Gene 1994; 140: 97-102.
121. Quintiliani R, Courvalin P. Conjugal transfer of the vancomycin resistance determinant vanB between enterococci involves the movement of large genetic elements from chromosome to chromosome. FEMS Microbiol Lett 1994; 119: 359-363.
122. Billot-Klein D, Gutmann L, Sable S, Guittet E, van Heijenoort J. Modification of peptidoglycan precursors is a common feature of the low-level vancomycin-resistant vanB type Enterococcus D366 and of the naturally glycopeptide-resistant species Lactobacillus casei, Pediococcus pentosaceus, Leuconostoc mesenteroides, and Enterococcus gallinarum. J Bacteriol 1994; 176: 2398-2405.
123. Woodford N, Johnson AP, Morrison D et al. Vancomycin-dependent enterococci in the United Kingdom. J Antimicrob Chemother 1994; 33: 1066.
124. Fraimow HS, Jungkind DL, Lander DW, Delso DR, Dean JL. Urinary tract infection with an Enterococcus faecalis isolate that requires vancomycin for growth. Ann Intern Med 1994; 121: 22-26.
125. Biavasco F, Giovanetti E, Montanari MP, Lupidi R, Varaldo PE. Development of in-vitro resistance to glycopeptide antibiotics: assessment of staphylococci of different species. J Antimicrob Chemother 1991; 27: 71-79.
126. Daum RS, Gupta S, Sabbagh R, Milewski WM. Characterization of Staphylococcus aureus isolates with decreased susceptibility to vancomycin and teicoplanin: isolation and purification of a constitutively produced protein associated with decreased susceptibility. J Infect Dis 1992; 166: 1066-1072.
127. Sanyal D, Greenwood D. An electronmicroscope study of glycopeptide antibiotic-resistant strains of Staphylococcus epidermidis. J Med Microbiol 1993; 39: 204-210.
128. O'Hare MD, Reynolds PE. Novel membrane proteins present in teicoplanin-resistant, vancomycin-sensitive, coagulase-negative Staphylococcus spp. J Antimicrob Chemother 1992; 30: 753-768.
129. Kaatz GW, Seo SM, Dorman NJ, Lerner SA. Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis. J Infect Dis 1990; 162: 103-108.
130. Noble WC, Virani Z, Cree RGA. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 1992; 72: 195-198.
131. Abraham EP, Chain E. An enzyme from bacteria able to destroy penicillin. Nature 1940; 146: 837.
132. Williams RJ, Yang Y-J, Livermore DM. Mechanisms by which imipenem may overcome resistance in Gram-negative bacilli. J Antimicrob Chemother 1986; 18 Suppl E: 9-13.
133. Gehrlein M, Leying H, Cullman W, Wendt S, Opferkuch W. Imipenem resistance in Acinetobacter baumanii is due to altered penicillin-binding proteins. Chemotherapy 1991; 37: 405-412.
134. Bergogne-Bérézin E, Joly-Guillou ML. Antibiotic resistance mechanisms in Acinetobacter. In: Towner KJ, Bergogne-Bérézin E, Fewson CA (eds) The biology of Acinetobacter: taxonomy, clinical importance, molecular biology, physiology, industrial relevance. New York, Plenum Press. 1991; 83 115.
135. Neuwirth C, Siebor E, Ducz J-M, Péchinot A. Kazmierczak A. Imipenem resistance in clinical isolates of Proteus mirabilis associated with alterations in penicillin-binding proteins. J Antimicrob Chemother 1995; 36: 335-342.
136. Nordmann P, Nicolas MH, Gutmann L. Penicillin-binding proteins of Rhodococcus equi: potential role in resistance to imipenem. Antimicrob Agents Chemother 1993; 37: 1406-1409.
137. Pederson SS, Pressler T, Høiby N, Bentzon MW, Cock C. Imipenem/cilastin treatment of multiresistant Pseudomonas aeruginosa lung infections in cystic fibrosis. J Antimicrob Chemother 1985; 16: 629-635.
138. Buscher KH, Cullman W, Dick W, Opferkuch W. Imipenem resistance in Pseudomonas aeruginosa resulting from diminished expression of an outer membrane protein. Antimicrob Agents Chemother 1987; 31: 703-708.
139. Trias J, Nikaido H, Protein D2 channel of the Pseudomonas aeruginosa outer membrane has a binding site for basic amino acids and peptides. J Biol Chem 1990; 265: 15680-15684.
140. Livermore DM. Interplay of impermeability and chromosomal β-lactamase activity in imipenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 1992; 36: 2046-2048.
141. Zhou XY, Kitzis M, Gutman L. Role of cephalosporinase in carbapenem resistance of clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1993; 37: 387-389.
142. Chen HY, Yuan M, Livermore DM. Mechanisms of resistance to β-lactam antibiotics amongst Pseudomonas aeruginosa isolates collected in the UK in 1993. J Med Microbiol 1995; 43: 300-309.
143. Rasmussen BA, Yang Y, Jacobus N, Bush K. Contribution of enzymatic properties, cell permeability, and enzyme expression to microbiological activities of β-lactams in three Bacteroides fragilis isolates that harbor a metallo-β-lactamase gene. Antimicrob Agents Chemother 1994; 38: 2116-2120.
144. Edwards R, Greenwood D. An investigation of β-lactamases from clinical isolates of Bacteroides species. J Med Microbiol 1992; 36: 89-95.
145. Livermore DM. β-lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557-584.
146. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995; 39: 1211-1233.
147. Yang Y, Wu P, Livermore DM. Biochemical characterization of a β-lactamase that hydrolyzes penems and carbapenems from two Serratia marcescens isolates. Antimicrob Agents Chemother 1990; 34: 755-758.
148. Naas T, Vandel L, Soughakoff W, Livermore DM, Nordmann P. Cloning and sequence analysis of the gene for a carbapenem-hydrolyzing Class A β-lactamase, Sme-1, from Serratia marcescens S6. Antimicrob Agents Chemother 1994; 38: 1262-1270.
149. Naas T, Nordmann P. Analysis of a carbapenem-hydrolyzing class A β-lactamase from Enterobacter cloacae and of its LysR-type regulatory protein. Proc Natl Acad Sci USA 1994; 91: 7693-7697.
150. Payne DJ, Metallo-β-lactamascs - a new therapeutic challenge. J Med Microbiol 1993; 39: 93-99.
151. Sutton BJ, Artymiuk PJ, Cordero-Borboa AK, Little C, Phillips DC, Waley SG. An X-ray crystallographic study of the β-lactamase II from Bacillus cereus at 0.35 nm resolution. Biochem J 1987; 249: 181-188.
152. Hawkey PM, Birkenhead D, Kerr KG, Newton KE, Hyde WA. Effect of divalent cations in bacteriological media on the susceptibility of Xanthomonas maltophilia to imipenem, with special reference to zinc ions. J Antimicrob Chemother 1993; 31: 47-55.
153. Fuji T, Sato K, Miyata K, Inoue M, Mitsuhashi S. Biochemical properties of β-lactamase produced by Legionella gormanii. Antimicrob Agents Chemother 1986; 29: 925-926.
154. Shannon K, King A, Phillips I. β-Lactamases with high activity against imipenem and Sch 34343 from Aeromonas hydrophila. J Antimicrob Chemother 1986; 17: 45-50.
155. Bakken JS, Sanders CC, Clark RB, Hori M. β-Lactam resistance in Aeromonus spp. caused by inducible β-lactamases active against penicillins, cephalosporins, and carbapenems. Antimicrob Agents Chemother 1988; 32: 1314-1319.
156. Iaconis JP, Sanders CC. Purification and characterization of inducible β-lactamases in Aeromonas spp. Antimicrob Agents Chemother 1990; 34: 44-51.
157. Rossolini GM, Zanchi A, Chiesurin A, Amicosante G, Satta G, Guglielmetti P. Distribution of cphA or related carbapenemase-encoding genes and production of carbapenemase activity in members of the genus Acromonas. Antimicrob Agents Chemother 1995; 39: 346-349.
158. Walsh TR, Payne DJ, MacGowan AP, Bennett PM. A clinical isolate of Aeromonus sobria with three chromosomally mediated inducible β-lactamases: a cephalosporinase. a penicillinase and a third enzyme, displaying carbapenemase activity. J Antimicrob Chemother 1995; 35: 271-279.
159. Hayes MV, Thomson CJ, Amyes SGB. Three β-lactamases isolated from Aeromonas salmonicida, including a carbapenemase not detectable by conventional methods. Eur J Clin Microbiol Infect Dis 1994; 13: 805-811.
160. Hayes MV, Thomson CJ, Amyes SGB. The 'hidden' carbapenemase of Aeromonas hydrophila. J Antimicrob Chemother 1996; 37: 33-44.
161. Bonfiglio G, Stefani S, Nicoletti G. Clinical isolate of a Xanthomonas maltophilia strain producing L-1-deficient and L-2-inducible β-lactamases. Chemotherapy 1995; 41: 121-124.
162. Paton R, Miles RS, Amyes SGB. Biochemical properties of inducible β-lactamases produced from Xanthomonas maltophilia. Antimicrob Agents Chemother 1994; 38: 2143-2149.
163. Payne DJ, Cramp R, Bateson JH, Neale J, Knowles D. Rapid identification of metallo- and serine β-lactamases. Antimicrob Agents Chemother 1994; 38: 991-996.
164. Baxter IA, Lambert PA. Isolation and partial purification of a carbapenem-hydrolysing metallo-β-lactamase from Pseudomonas cepacia. FEMS Microbiol Lett 1994; 122: 251-256.
165. Yotsuji A, Minami S, Inoue M, Mitsuhashi S. Properties of novel β-lactamase produced by Bacteroides fragilis. Antimicrob Agents Chemother 1983; 24: 925-929.
166. Thompson JS, Malamy MH. Sequencing the gene for an imipenem-cefoxitin-hydrolyzing enzyme (CfiA) from Bacteroides fragilis TAL2480 reveals strong similarity between CfiA and Bacillus cereus β-lactamase II. J Bacteriol 1990; 172: 2584-2593.
167. Podglajen I, Breuil J, Collatz E. Insertion of a novel DNA sequence, IS1186, upstream of the silent carbapenemase gene cfiA, promotes expression of carbapenem resistance in clinical isolates of Bacteroides fragilis. Mol Microbiol 1994; 12: 105-114.
168. Bandoh K, Ueno K, Watanabe K, Kato N. Susceptibility patterns and resistance to imipenem in the Bacteroides fragilis group species in Japan: a 4-year study. Clin Infect Dis 1993; 16 Suppl 4: S382-S386.
169. Watanabe M, Iyobe S, Inoue M, Mitsuhashi S. Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1991; 35: 147-151.
170. Osano F, Arakawa Y, Wacharotayankun R et al. Molecular characterization of an enterobacterial metallo-β-lactamase found in a clinical isolate of Serratia marcescens that shows imipenem resistance. Antimicrob Agents Chemother 1994; 38: 71-78.
171. Minami S, Akama M, Araki H et al. Imipenem and cephem resistant Pseudomonas aeruginosa carrying plasmids coding for class B β-lactamase. J Antimicrob Chemother 1996; 37: 433-444.
172. IMP among clinically isolated strains of Serratia marcescens. Antimicrob Agents Chemother 1995; 39: 824-829.
173. Senda K, Arakawa Y, Ito H et at. PCR detection of metallo-β-lactamase producing Pseudomonas aeruginosa resistant to carbapenem. 96th Annual Meeting of ASM, New Orleans, Washington, DC, American Society for Microbiology. 1996: Abstract A45, p. 141.
174. Senda K, Arakawa Y, Nakashima K et al. Multifocal outbreaks of metallo-β-lactamase-producing Pseudomonas aeruginosa resistant to broad-spectrum β-lactams. including carbapenems. Antimicrob Agents Chemother 1996; 40: 349-353.
175. Ambler RP, Coulson AKN, Frere JM et al. A standard numbering system for the class A β-lactamases. Biochem J 1991; 276: 269-270.
176. Shanahan PMA, Thomson CJ, Amyes SGB. β-Lactam resistance in normal faecal flora from South Africa. Epidemiol Infect 1995; 115: 243-253.
177. Nandivada LS, Amyes SGB. Plasmid-mediated β-lactam resistance in pathogenic Gram-negative bacteria isolated in South India. J Antimicrob Chemother 1990; 26: 279-290.
178. Shanahan PMA, Thomson CJ, Amyes SGB. β-Lactam resistance in aerobic faecal flora from general practice patients in the U.K. Eur J Clin Microbiol Infect Dis 1994; 13: 760-763.
179. Henquell C, Chanal C, Sirot D, Labia R, Sirot J. Molecular characterization of nine different types of mutants among 107 inhibitor-resistant TEM β-lactamases from clinical isolates of Escherichia coli. Antimicrob Agents Chemother 1995; 39: 427-430.
180. Jelsch C, Lenfant F, Masson JM, Samama JP. Crystallization and preliminary cristallographic data on Escherichia coli TEM-1 β-lactamase. J Mol Biol 1992; 223: 377-380.
181. Jelsch C, Mourey L, Masson JM, Samama JP. Crystal structure of Escherichia coli TEM-1 β-lactamase at 1.8-A resolution. Proteins 1993; 16: 364-383.
182. Payne DJ, Marriott MS, Amyes SGB. Characterisation of a unique ceftazidime-hydrolysing β-lactamase. TEM-E2. J Med Microbiol 1990; 32: 131-134.
183. Du Bois SK, Marriott MS, Amyes SGB. THM- and SHV-derived extended-spectrum β-lactamases: relationship between selection, structure and function. J Antimicrob Chemother 1995; 35: 7-22.
184. Payne DJ, Amyes SGB. Transferable resistance to extended-spectrum β-lactams: a major threat or a minor inconvenience? J Antimicrob Chemother 1991; 27: 255-261.
185. Sowek JA, Singer SB, Ohringer S et al. Substitution of lysine at position 104 or 240 of TEM-1 pTZ18R β-lactamase enhances the effect of serine-164 substitution on hydrolysis or affinity for cephalosporins and the monobactam aztreonam. Biochemistry 1991; 30: 3179-3188.
186. Jarlier V, Nicolas MH, Fournier G, Philippon A. Extended broad-spectrum β-lactamases conferring transferable resistance to newer β-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis 1988; 10: 867-878.
187. Knothe H, Shah P, Kremery V, Antal M, Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae. Infection 1983; 11: 315-317.
188. Huletsky A, Couture F, Leversque RC. Nucleotide sequence and phylogeny of SHV-2 β-lactamase. Antimicrob Agents Chemother 1990; 34: 1725-1732.
189. Huletsky A, Knox JR, Levesque RC. Role of Ser-238 and Lys-240 in the hydrolysis of 3rd-generation cephalosporins by SHV-type β-lactamases probed by site-directed mutagenesis and 3-dimensional modeling. J Biol Chem 1993; 268: 3690-3697.
190. Vatopoulos AC, Philippon A, Tzouvelekis LS, Komninou Z, Legakis NJ. Prevalence of a transferable SHV-5 type β-lactamase in clinical isolates of Klebsiella pneumoniae and Escherichita coli in Greece. J Antimicrob Chemother 1990; 26: 635-648.
191. Bauernfeind A, Rosenthal E, Eberlein E, Holley M, Schweighart S. Spread of Klebsiella pneumoniae producing SHV-5 β-lactamase among hospitalized patients. Infection 1993; 21: 18-22.
192. Bradford PA, Urban C, Jaiswal A et al. SHV-7, a novel cefotaxime-hydrolyzing β-lactamase, identified in Escherichia coli isolates from hospitalized nursing home patients. Antimicrob Agents Chemother 1995; 39: 899-905.
193. Du Bois SK, Marriott MS, Amyes SGB. Can clavulanic acid reverse extended-spectrum β-lactamase mutations? ICAAC, New Orleans, Washington, DC, American Society for Microbiology. 1993: 582 (Abstract).
194. Podbielski A, Schonling J, Melzer B, Warnatz K, Leusch HG. Molecular characterization of a new plasmid-encoded SHV-type β-lactamase (SHV-2 variant) conferring high-level cefotaxime resistance upon Klebsiella pneumoniae. J Gen Microbiol 1991; 137: 569-578.
195. Thomson CJ, Amyes SGB. TRC-1: emergence of a clavulanic acid-resistant TEM β-lactamase in a clinical strain. FEMS Microbiol Lett 1992; 91: 113-117.
196. Vedel G, Belaaouaj A, Gilly L et al. Clinical isolates of Escherichiu coli producing TRI β-lactamases - novel TEM-enzymes conferring resistance to β-lactamase inhibitors. J Antimicrob Chemother 1992; 30: 449-462.
197. Henquell C, Sirot D, Chanal C et al. Frequency of inhibitor-resistant TBM β-lactamases in Escherichia coli isolates from urinary tract infections in France. J Antimicrob Chemother 1994; 34: 707-714.
198. Intercontinental Medical Statistics, Ruislip, Middlesex, UK. 1995.
199. Cairns J. The chromosome of Escherichia coli. Cold Spring Harbor Symp Quant Biol 1963; 28: 43-46.
200. Gellert M, Misuuchi K, O'Dea MH, Nash HA. DNA gyrase: an enzyme that introduces superhelical turns into DNA. Proc Natl Acad Sci USA 1976; 73: 3872-3876.
201. Sugino A, Peebles CL, Kruezer KN, Cozzarelli NR. Mechanism of action of nalidixic acid: purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme. Proc Natl Acad Sci USA 1977; 74: 4767-4771.
202. Hooper DC. Quinolone mode of action. Drugs 1995; 49 Suppl 2: 10-15.
203. Vincent S, Glauner B, Gutmann L. Lytic effect of two fluoroquinolones, ofloxacin and pefloxacin, on Escherichia coli W7 and its consequences on peptidoglycan composition. Antimicrob Agents Chemother 1991; 35: 1381-1385.
204. Cozens RM, Markiewicz Z, Tuomanen E. Role of autolysins in the activities of imipenem and CGP 31608, a novel penem, against slowly growing bacteria. Antimicrob Agents Chemother 1989; 33: 1819-1821.
205. Wolfson JS, Hooper DC, McHugh GL, Bozza MA, Swartz MN. Mutants of Escherichia coli K12 exhibiting reduced killing by both quinolone and β-lactam antimicrobial agents. Antimicrob Agents Chemother 1990; 34: 1938-1943.
206. Munshi MH, Haider K, Rahaman MM, Sack DA, Ahmed ZV, Morshed MG. Plasmid-mediated resistance to nalidixic acid in Shigella dysenteriae type 1. Lancet 1987; ii: 419-421.
207. Tanaka M, Ishii H, Sato K, Osada Y, Nishino T. Characterization of high level quinolone resistance in Staphylococcus aureus. 31st ICAAC, Chicago, Washington, DC, American Society for Microbiology. 1991: Abstract 808, p. 233.
208. Courvalin P. Plasmid-mediated 4-quinolone resistance: a real or apparent absence? Antimicrob Agents Chemother 1990; 34: 681-684.
209. Yoshida H, Bogaki M, Nakamura S, Ubukata K, Konno M. Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones. J Bacteriol 1990; 172: 6942-6949.
210. Cambau E, Gutmann L. Mechanisms of resistance to quinolones. Drugs 1993; 45 Suppl 3: 5-23.
211. Yoshida H, Bogaki H, Nakamura M, Nakamura S. Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob Agents Chemother 1990; 34: 1271-1272.
212. Yamagishi J, Yoshida H, Yamagoshi M, Nakamura S. Nalidixic acid-resistant mutations of the gyrB gene of Escherichia coli. Mol Gen Genet 1986; 204: 367-373.
213. Chapman JS, Georgopapadakou NH. Routes of quinolone permeation in Escherichia coli. Antimicrob Agents Chemother 1988; 32: 438-442.
214. Cohen SP, McMurry LM, Hooper DC, Wolfson JS, Levy SB. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistance (Mar) Escherichia coli selected by tetracycline or chloramphenicol: decreased drug accumulation associated with changes in addition to OmpF reduction. Antimicrob Agents Chemother 1989; 33: 1318-1325.
215. Ohshita Y, Hiramatsu K, Yokota T. A point mutation in norA gene is responsible for quinolone resistance in Staphylococcus aureus. Biochem Biophys Res Commun 1990; 172: 1028-1034.
216. Kaatz GW, Seo SM. Up regulation of norA1199 results in fluoroquinolone (FQ) resistance in Staphylococcus aureus (SA). 32nd ICAAC, Anaheim, CA. Washington, DC, American Society for Microbiology. 1992: Abstract 1481, p. 357.
217. Trucksis M, Wolfson JS, Hooper DC. A novel locus conferring fluoroquinolone resistance in Staphylococcus aureus. J Bacteriol 1991; 173: 5854-5860.
218. Thornsberry C. Susceptibility of clinical bacterial isolates to ciprofloxacin in the United States. Infection 1994; 22 Suppl 2: S80-S89.
219. Blondeau J, Yaschuk Y and the Canadian Ciprofloxacin Study Group. Canadian Ciprofloxacin Susceptibility Study: comparative study from 15 medical centers. Antimicrob Agents Chemother 1996; 40: 1729-1732.
220. Tillotson G, Herbert JJF. Comparison of antibiotic susceptibility levels in the United Kingdom. 4th European Congress of Clinical Microbiology and Infectious Diseases, Nice. France. 1989: Abstract 431, p 23.
221. Kresken M, Hafner D, Mittermayer H et al. Prevalence of fluoroquinolone resistance in Europe. Infection 1994; 22 Suppl 2: S90-S98.
222. Doern GV, Brueggemann A, Holley HP, Rauch AM. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother 1996; 40: 1208-1213.
223. Goldstein FW, Acar JF. Epidemiology of quinolone resistance: Europe and North and South America. Drugs 1995; 49 Suppl 2: 36-42.
224. Budnick LD, Schaefler S. Ciprofloxacin-resistant methicillin-resistant Staphylococcus aureus in New York health care facilities, 1988. The New York MRSA Study Group. Am J Public Health 1990; 80: 810-813.
225. Schaberg DR, Dillon WI, Terpenning MS, Robinson KA, Bradley SF, Kauffman CA. Increasing resistance of enterococci to ciprofloxacin. Antimicrob Agents Chemother 1992; 36: 2533-2535.
226. King A, Phillips I, Amyes SGB, Paton R, Levin C, Tillotson G. MIC audit of routine ciprofloxacin sensitivity testing. Drugs 1993; 45 Suppl 3: 163-164.
227. Thomson CJ, Paton RH, Hood J, Miles RS, Amyes SGB. Antibiotic resistance in urinary bacteria isolated in central Scotland. Int J Antimicrob Agents 1992; 1: 223-228.
228. MacGowan AP, Brown NM, Holt HA, Lovering AM, McCulloch SY, Reeves DS. An eight-year survey of the antimicrobial susceptibility patterns of 85,971 bacteria isolated from patients in a district general hospital and the local community. J Antimicrob Chemother 1993; 31: 543-557.
229. Amyes SGB, Baird DR, Crook DW et al. A multicentre study of the in-vitro activity of cefotaxime, cefuroxime. ceftazidime. ofloxacin and ciprofloxacin against blood and urinary pathogens. J Antimicrob Chemother 1994; 34: 639-648.
230. Frost JA, Kelleher A, Rowe B. Increasing ciprofloxacin resistance in salmonellas in England and Wales 1991 - 1994. J Antimicrob Chemother 1996; 37: 85-91.
231. Brown JC, Shanahan PMA, Jesudason MV, Thomson CJ, Amyes SGB. Mutations responsible for reduced susceptibility to 4-quinolones in clinical isolates of multi-resistant Salmonella typhi in India. J Antimicrob Chemother 1996; 37: 891-900.
232. Gillespie SH, Fox R, Patel S, Ngowi F, Tillotson GS. Antibiotic susceptibility of Enterobacteriaceae isolated from patients in Northern Tanzania. J Antimicrob Chemother 1992; 29: 227-229.
233. Coronado VR, Edwards JR, Culver DH, Gaynes RP and the National Nosocomial Infections Surveillance (NNIS) System. Ciprofloxacin resistance among nosocomial Pseudomonas aeruginosa and Staphylococcus aureus in the United States. Infect Control Hosp Epidemiol 1995; 16: 71-75.
234. Reina J, Borrell N, Serra A. Emergence of resistance to erythromycin and fluoroquinolones in thermotolerant Campylobacter strains isolated from feces 1987 1991. Eur J Clin Microbiol Infect Dis 1992; 11: 1163-1166.
235. Child J, Andrews J, Boswell F, Brenwald N, Wise R. The in-vitro activity of CP99.219, a new naphthylpyridone antimicrobial agent: a comparison with fluoroquinolone agents. J Antimicrob Chemother 1995; 35: 869-876.
236. Marco F, Jones RN, Hoban DJ, Pignatari AC, Yamane N, Frei R. In-vitro activity of OPC-17116 against more than 6000 consecutive clinical isolates: a multicentre international study. J Antimicrob Chemother 1994; 33: 647-654.
237. Flamm RK, Vojtko C, Chu DTW et al. In vitro evaluation of ABT-719, a novel DNA gyrase inhibitor. Antimicrob Agents Chemother 1995; 39: 964-970.
238. Hoshino K, Kutamura A, Morrissey I, Sato K, Kato J-I, Ikeda H. Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition. Antimicrob Agents Chemother 1994; 38: 2623-2627.
239. Timmis KN, Gonzalez-Carrero MI, Sekizaki T, Rojo F. Biological activities specified by antibiotic resistance plasmids. J Antimicrob Chemother 1986: 18 Suppl C:1 12.
240. Cundliffe E. How antibiotic-producing organisms avoid suicide. Annu Rev Microbiol 1989; 43: 207-233.
241. Leveau JY, Bouix M. Microbiologie industrielle. Les microorganismes d'intérêt industriel. Collection Sciences et Techniques Agro-Alimentaires. Technique & Documentation, Paris. Lavoisier.
242. Davies J, Houk C, Yagisawa M, White TJ. Occurrence and function of aminoglycoside-modifying enzymes. In: Sehek OK, Laskin AJ (eds) Genetics of industrial microorganisms. Washington, DC, American Society for Microbiology. 1979; 166-169.
243. Datta N, Hughes VM. Plasmids of the same Inc groups in Enterobacteria before and after the medical use of antibiotics. Nature 1983; 306: 616-617.
244. Jacoby GA. Extrachromosomal resistance in gram-negative organisms: the evolution of β-lactamase. Trends Microbiol 1994; 2: 357-360.
245. Courvalin P. Transfer of antibiotic resistance genes between gram-positive and gram-negative bacteria. Antimicrob Agents Chemother 1994; 38: 1447-1451.
246. Committee on Human Health Risk Assessment of Using Subtherapeutic Antibiotics in Animal Feeds. Human health risks with the subtherapeutic use of penicillin or tetracyclines in animal feed. Washington, DC, National Academy Press. 1989.
247. Pérez-Trallero E, Zigorraga C. Resistance to antimicrobial agents as a public health problem: importance of the use of antibiotics in animals. Int J Antimicrob Agents 1995; 6: 59-63.
248. Donnelly JP, Voss A, Witte W, Murray BE. Does the use in animals of antimicrobial agents, including glycopeptide antibiotics, influence the efficacy of antimicrobial therapy in humans? J Antimicrob Chemother 1996; 37: 389-390.
249. Trieu-Cuot P, Courvalin P. Evolution and transfer of aminoglycoside resistance genes under natural conditions. J Antimicrob Chemother 1986; 18 Suppl C: 93-102.
250. Endtz HP, Ruijs GJ, Van Klingeren B, Jansen WH, van der Reyden T, Mouton RP. Quinolone resistance in campylobacter isolated from man and poultry following the introduction of fluoroquinolones in veterinary medicine. J Antimicrob Chemother 1991; 27: 199-208.
251. Linton AH. Flow of resistance genes in the environment and from animals to man. J Antimicrob Chemother 1986; 18 Suppl C: 189-197.
252. Anderson FS. The ecology of transferable drug resistance in the enterobacteria. Annu Rev Microbiol 1968; 22: 131-180.
253. Young H-K. Antimicrobial resistance spread in aquatic environments. J Antimicrob Chemother 1993; 31: 627-635.
254. Hawkey PM. Resistant bacteria in the normal human flora. J Antimicrob Chemother 1986; 18 Suppl C: 133-139.
255. Bergogne-Bérézin E. Resistance of Acinetobacter spp. to antimicrobials. Overview of clinical resistance patterns and therapeutic problems. In: Bergogne-Bérézin E, Joly-Guillou ML, Towner KJ (eds) Acinetobacter, microbiology, epidemiology, infections, management. Boca Raton, CRC Press. 1996: 133-138.
256. Jacobson KF, Cohen SH, Inciardi JF et al. The relationship between antecedent antibiotic use and resistance to extended-spectrum cephalosporins in group I β-lactamase-producing organisms. Clin Infect Dis 1995; 21: 1107-1113.
257. Cohen ML. Antimicrobial resistance: prognosis for public health. Trends Microbiol 1994; 2: 422-425.
258. Courcol RJ, Pinkas M, Martin GR. A seven year survey of antibiotic susceptibility and its relationship with usage. J Antimicrob Chemother 1989; 23: 441-451.
259. Buisson Y, Tran Van Nhieu G, Ginot L et al. Nosocomial outbreaks due to amikacin-resistant tobramycin-sensitive Acinetobacter species: correlation with amikacin usage. J Hosp Infect 1990; 15: 83-93.
260. Nissinen A, Grönroos P, Huovinen P et al. Development of β-lactamase-mediated resistance to penicillin in middle-ear isolates of Moraxella catarrhalis in Finnish children. 1978 1993. Clin Infect Dis 1995; 21: 1193-1196.
261. Janknegt R, van der Meer JWM. Sequential therapy with intravenous and oral cephalosporins. J Antimicrob Chemother 1994; 33: 169-177.
262. Quintiliani R, Nightingale C. Transitional antibiotic therapy. Infect Dis Clin Pract 1994; 3 Suppl 3: S161-S167.
263. Mandell GL. Delivery of antibiotics by phagocytes. Clin Infect Dis 1994; 19: 922-925.
264. Kreuter J. Liposomes and nanoparticles as vehicles for antibiotics. Infection 1991; 19 Suppl 4: S224-S228.